| Literature DB >> 33429787 |
Xue-Ying Zhang1, Li-Li Zhou2, Yan Jiao3, Yan-Qing Li4, Yi-Nuo Guan5, Yue-Chen Zhao6, Lian-Wen Zheng1.
Abstract
ABSTRACT: Ovarian cancer (OC), a common malignant heterogeneous gynecological tumor, is the primary cause of cancer-related death in women worldwide. Adenylate kinase (AK) 7 belongs to the adenylate kinase (AK) family and is a cytosolic isoform of AK. Recent studies have demonstrated that AK7 is expressed in several human diseases, including cancer. However, there is a scarcity of reports on the relationship between AK7 and OC. Here, we compared the expression of AK7 in normal and cancerous ovarian tissues from The Cancer Genome Atlas database and used the c2 test to assess the correlation between AK7 levels and the clinical symptoms of OC. Finally, the prognostic significance of AK7 in OC was determined using the Kaplan-Meier analyses and Cox regression and performed gene set enrichment analysis to detect any relevant signaling pathways. We found that AK7 levels were substantially downregulated in OC than that in normal ovarian tissues (P < .001). Low AK7 levels were related to the patients' age (P = .0093) in OC. The median overall survival (OS) of patients with low AK7-expressing OC was shorter than patients with high AK7-expressing OC (P = .019). The Cox regression analysis (multivariate) identified low AK7 levels were independently related to the prognosis of OC (HR 1.34; P = .048). Our study demonstrated that the downregulated levels of AK7 could serve as an independent prognostic indicator for the OS in OC. Additionally, gene set enrichment analysis revealed that EMT, apical junction, TGF-b signaling, UV response, and myogenesis were associated in the low AK7 expression phenotype (NOM P < .05).Entities:
Mesh:
Substances:
Year: 2021 PMID: 33429787 PMCID: PMC7793326 DOI: 10.1097/MD.0000000000024134
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Demographic and clinical characteristics of TCGA cohort.
| Characteristics | Numbers of cases |
| Age | |
| <55 | 113 (36.69) |
| >=55 | 195 (63.31) |
| Subdivision | |
| NA | 17 (5.52) |
| Bilateral | 212 (68.83) |
| Left | 37 (12.01) |
| Right | 42 (13.64) |
| Stage | |
| NA | 2 (0.65) |
| I | 1 (0.32) |
| II | 22 (7.14) |
| III | 245 (79.55) |
| IV | 38 (12.34) |
| Longest dimension | |
| Large | 124 (46.1) |
| Small | 145 (53.9) |
| Lymphatic invasion | |
| NA | 180 (58.44) |
| NO | 44 (14.29) |
| YES | 84 (27.27) |
| Histologic grade | |
| NA | 2 (0.65) |
| G1 | 1 (0.32) |
| G2 | 37 (12.01) |
| G3 | 261 (84.74) |
| G4 | 1 (0.32) |
| GB | 2 (0.65) |
| GX | 4 (1.3) |
| New type | |
| NA | 145 (47.08) |
| Locoregional | 4 (1.3) |
| Metastatic | 1 (0.32) |
| Progression | 12 (3.9) |
| Recurrence | 146 (47.4) |
| Sample type | |
| Primary Tumor | 303 (98.38) |
| Recurrent Tumor | 5 (1.62) |
| Vital status | |
| Deceased | 184 (59.74) |
| Living | 124 (40.26) |
| AK7 | |
| High | 154 (50) |
| Low | 154 (50) |
Figure 1AK7 expression in OC. Boxplots show the difference in AK7 expression grouped by stage, histological grade, new type, vital status, subdivision, lymphatic invasion, and patient age. AK7 = adenylate kinase 7.
Association of AK7 mRNA expression in ovarian cancer tissues with clinicopathologic variables.
| AK7 mRNA expression | ||||||||
| Parameter | Variable | N | High | % | Low | % | ||
| Age | <55 | 113 | 68 | (44.16) | 45 | (29.22) | 6.7652 | .0093 |
| >=55 | 195 | 86 | (55.84) | 109 | (70.78) | |||
| Subdivision | Bilateral | 212 | 111 | (74.5) | 101 | (71.13) | 4.0109 | .1346 |
| Left | 37 | 22 | (14.77) | 15 | (10.56) | |||
| Right | 42 | 16 | (10.74) | 26 | (18.31) | |||
| Stage | I | 1 | 1 | (0.65) | 0 | (0) | 2.2183 | .5284 |
| II | 22 | 12 | (7.79) | 10 | (6.58) | |||
| III | 245 | 125 | (81.17) | 120 | (78.95) | |||
| IV | 38 | 16 | (10.39) | 22 | (14.47) | |||
| Longest dimension | Large | 124 | 60 | (43.8) | 64 | (48.48) | 0.4212 | .5164 |
| Small | 145 | 77 | (56.2) | 68 | (51.52) | |||
| Lymphatic invasion | No | 44 | 18 | (27.27) | 26 | (41.94) | 2.4315 | .1189 |
| Yes | 84 | 48 | (72.73) | 36 | (58.06) | |||
| Histologic grade | G1 | 1 | 0 | (0) | 1 | (0.66) | 5.5678 | .3506 |
| G2 | 37 | 24 | (15.58) | 13 | (8.55) | |||
| G3 | 261 | 126 | (81.82) | 135 | (88.82) | |||
| G4 | 1 | 1 | (0.65) | 0 | (0) | |||
| GB | 2 | 1 | (0.65) | 1 | (0.66) | |||
| GX | 4 | 2 | (1.3) | 2 | (1.32) | |||
| New type | Locoregional | 4 | 4 | (4.82) | 0 | (0) | 5.3073 | .1506 |
| Metastatic | 1 | 0 | (0) | 1 | (1.25) | |||
| Progression | 12 | 5 | (6.02) | 7 | (8.75) | |||
| Recurrence | 146 | 74 | (89.16) | 72 | (90) | |||
| Sample type | Primary Tumor | 303 | 151 | (98.05) | 152 | (98.7) | 0 | 1 |
| Recurrent Tumor | 5 | 3 | (1.95) | 2 | (1.3) | |||
| Vital status | Deceased | 184 | 92 | (59.74) | 92 | (59.74) | 0 | 1 |
| Living | 124 | 62 | (40.26) | 62 | (40.26) | |||
Figure 2The PV of AK7 in patients with OC. Kaplan-Meier curves for the survival of patients with OC based on AK7 expression in cancerous ovarian tissues. AK7 = adenylate kinase 7.
Univariate and multivariate analyses of overall survival in patients with ovarian cancer.
| Univariate analysis | Multivariate analysis | |||||
| Parameters | Hazard Ratio | CI 95 | Hazard Ratio | CI 95 | ||
| Age | 1.63 | 1.19–2.24 | .003 | 1.57 | 1.14–2.16 | .005 |
| Subdivision | 0.84 | 0.67–1.04 | .101 | |||
| Stage | 1.09 | 0.8–1.5 | .581 | |||
| Longest dimension | 1.12 | 0.82–1.52 | .485 | |||
| Lymphatic invasion | 1.02 | 0.85–1.23 | .798 | |||
| Histologic grade | 1.12 | 0.88–1.42 | .349 | |||
| New type | 0.99 | 0.63–1.55 | .951 | |||
| Sample type | 0.43 | 0.11–1.73 | .235 | |||
| AK7 | 1.41 | 1.06–1.89 | .02 | 1.34 | 1–1.8 | .048 |
GSEA enrichment plot in low ABCB9 phenotype.
| Gene set | ES | NES | NOM |
| HALLMARK_epithelial mesenchymal transition | 0.64390194 | 1.8245728 | .019880716 |
| HALLMARK_UV response | 0.41891807 | 1.5772356 | .029940119 |
| HALLMARK_TGF-beta signaling | 0.48144048 | 1.5725749 | .03952569 |
| HALLMARK_myogenesis | 0.43896723 | 1.5351363 | .043052837 |
| HALLMARK_apical junction | 0.3967964 | 1.5181613 | .042 |
Figure 3Enrichment plots from gene set enrichment analysis.